Interferon beta tied to spike in thrombotic microangiopathy

March 27, 2014
Interferon beta tied to spike in thrombotic microangiopathy

(HealthDay)—There has been an unusually high number of cases of thrombotic microangiopathy associated with severe or malignant hypertension in patients with multiple sclerosis who were receiving therapy with recombinant interferon beta, according to a letter to the editor published in the March 27 issue of the New England Journal of Medicine.

David Hunt, Ph.D., from Edinburgh University in the United Kingdom, and colleagues reviewed case histories and pharmacy records to describe an unexpectedly high number of cases of thrombotic microangiopathy associated with severe or malignant hypertension in four patients with who were receiving therapy with recombinant interferon beta in South Scotland. All patients presented after years of well-tolerated treatment with interferon beta.

The researchers found no genetic or other causal factor for thrombotic microangiopathy, but did note a significant association with a common manufacturing source of interferon beta (Rebif, Merck). Geographical and temporal distribution of the hemolytic-uremic syndrome and thrombotic thrombocytopenic purpura reports shows that very few cases were reported globally in the first nine years of safety monitoring, but that there has been a recent increase in reports from countries that share the same formulation as that used in the United Kingdom.

"We did not detect such patterns or trends in the safety data from a similar recombinant product, suggesting that further investigation of the association with changes in manufacturing may be worthwhile," the authors write.

Explore further: Interleukin 17F level and interferon beta response in patients with multiple sclerosis

More information: Full Text

Related Stories

New link found between MS treatment and vitamin D

July 30, 2012

(Medical Xpress) -- A new study by researchers at the Menzies Research Institute Tasmania (Menzies) suggests that one of the main treatments for multiple sclerosis (MS) may also increase the amount of vitamin D patients receive ...

Hepatitis C drug can cause depression

May 1, 2012

There's a high rate of depression among patients with hepatitis C, but a standard treatment for the disease includes a drug, interferon, that can cause depression.

Recommended for you

Aspirin regimen for older adults has long-term benefits

November 30, 2016

For older Americans with a high risk of heart disease, taking low-dose aspirin every day could reduce their risk of a heart attack, prevent some cancers and cancer death, extend their lives and save the lives of hundreds ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.